Mira Pharmaceuticals Inc (MIRA) Stock Price, Quote & News

Company Profile

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic st...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 786 432 9792

Website: mirapharmaceuticals.com

Address:

1200 Brickell Avenue, Suite 1950 #1183, Miami, United States

Gaussminigun Jan. 14 at 5:25 AM

$MIRA YOU'RE LETTING ME DOWN KETAMINE........which I guess is what you're supposed to do

0 · Reply

Tristan2024 Jan. 13 at 9:09 PM

$BCAB $BMEA $IREN $MIRA $TELO

0 · Reply

OpenOutcrier Jan. 13 at 9:01 PM

RECAP 1/13 +Pos Comments: $IREN + HC Wainwright $TELO $MIRA $AAPG $BMEA $BCAB + Rondman & Renshaw Live Breaking trading news www.openoutcrier.com

0 · Reply

KPW963 Jan. 13 at 3:57 PM

$MIRA

0 · Reply

Jaespresso Jan. 12 at 10:00 PM

$MIRA

0 · Reply

MrWolf19 Jan. 12 at 3:05 PM

$MIRA

0 · Reply

KPW963 Jan. 12 at 1:40 PM

$MIRA

0 · Reply

Jaespresso Jan. 9 at 2:49 PM

$MIRA

0 · Reply

MREricPirate Jan. 9 at 8:48 AM

$MIRA waiting on the MAD results after that they should be starting phase 2 on Ketamir-2

0 · Reply

_Jean123 Jan. 8 at 12:57 AM

🚨 $MIRA - GAME CHANGER ALERT! PHASE 1 SAD RESULTS ARE SUCCESSFUL! 🚨 just proved the science! 🧪 Safety validated, zero serious adverse effects, and the path to FDA Fast Track is now wide open! This is no longer just a "penny stock"—it’s a clinical-stage 🛡️💎 🔥 WHY THE BULLS ARE LOADING: ✅ Phase 1 SAD Success: Proven safety in humans. The biggest hurdle is GONE. ✅ Massive Market: Targeting $10B+ in Depression & Neuropathic Pain with oral Ketamir-2. ✅ Deep Value: Currently trading under $2.00 while the science is worth 10x more. 🎯 TARGETS: T1: $2.95 (Gap Fill) T2: $6.00 (FDA Fast Track Hype) T3: $11.00 (Full Science Parabolic) LOAD THE DIP. TRUST THE SCIENCE. JOIN THE RUN! 🚀🚀🚀 #MIRA #FDA #Biotech #Success #Ketamine #Moonshot #ClinicalTrial #SADSuccess #Nasdaq READ THE OFFICIAL NEWS HERE: https://mirapharmaceuticals.com/press-releases/mira-pharmaceuticals-announces-favorable-topline-results-from-phase-1-sad-study-of-oral-ketamir-2-a-next-generation-non-scheduled-ketamine-analog/

0 · Reply

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

Oct 16, 2025, 7:30 AM EDT - 3 months ago

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain

Sep 30, 2025, 7:30 AM EDT - 3 months ago

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

Sep 22, 2025, 8:00 AM EDT - 4 months ago

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

Sep 16, 2025, 7:30 AM EDT - 4 months ago

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

Sep 12, 2025, 7:30 AM EDT - 4 months ago

MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

Aug 19, 2025, 8:30 AM EDT - 5 months ago

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

Aug 12, 2025, 8:30 AM EDT - 5 months ago

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin

Jul 30, 2025, 7:30 AM EDT - 5 months ago

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study

Jul 29, 2025, 7:30 AM EDT - 6 months ago

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

Jul 11, 2025, 8:00 AM EDT - 6 months ago

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

Jul 3, 2025, 8:00 AM EDT - 6 months ago

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

Jun 30, 2025, 8:00 AM EDT - 7 months ago

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition

Jun 25, 2025, 8:00 AM EDT - 7 months ago

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects

Jun 18, 2025, 8:30 AM EDT - 7 months ago

MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

May 28, 2025, 8:30 AM EDT - 8 months ago

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

May 8, 2025, 8:00 AM EDT - 8 months ago

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

May 6, 2025, 8:00 AM EDT - 9 months ago

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

Apr 23, 2025, 8:00 AM EDT - 9 months ago

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

Apr 16, 2025, 8:00 AM EDT - 9 months ago

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

Apr 1, 2025, 8:00 AM EDT - 10 months ago

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

Mar 24, 2025, 7:30 AM EDT - 10 months ago

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

Mar 13, 2025, 8:00 AM EDT - 10 months ago

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

Mar 4, 2025, 8:00 AM EST - 11 months ago

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

Dec 19, 2024, 9:00 AM EST - 1 year ago

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

Dec 10, 2024, 8:30 AM EST - 1 year ago

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

Nov 20, 2024, 7:44 AM EST - 1 year ago

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

Oct 28, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

Oct 21, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

Sep 27, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

Sep 18, 2024, 7:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

Sep 11, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

Aug 26, 2024, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

Aug 19, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

Aug 12, 2024, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

Jul 25, 2024, 7:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action

Jul 22, 2024, 2:33 PM EDT - 1 year ago

S&P 500 Gains 1%; MIRA Pharmaceuticals Shares Spike Higher

Jul 22, 2024, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

Jun 24, 2024, 8:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

Jun 17, 2024, 2:07 PM EDT - 1 year ago

MIRA Announces Positive Test Results

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year

May 29, 2024, 8:45 AM EDT - 1 year ago

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

May 21, 2024, 8:45 AM EDT - 1 year ago

MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog

May 20, 2024, 8:00 AM EDT - 1 year ago

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission

Mar 21, 2024, 11:04 AM EDT - 1 year ago

MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor

Feb 5, 2024, 8:30 AM EST - 2 years ago

MIRA Pharmaceuticals Provides Corporate Update

Dec 4, 2023, 8:00 AM EST - 2 years ago

MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations

Nov 29, 2023, 8:00 AM EST - 2 years ago

MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%

Gaussminigun Jan. 14 at 5:25 AM

$MIRA YOU'RE LETTING ME DOWN KETAMINE........which I guess is what you're supposed to do

0 · Reply

Tristan2024 Jan. 13 at 9:09 PM

$BCAB $BMEA $IREN $MIRA $TELO

0 · Reply

OpenOutcrier Jan. 13 at 9:01 PM

RECAP 1/13 +Pos Comments: $IREN + HC Wainwright $TELO $MIRA $AAPG $BMEA $BCAB + Rondman & Renshaw Live Breaking trading news www.openoutcrier.com

0 · Reply

KPW963 Jan. 13 at 3:57 PM

$MIRA

0 · Reply

Jaespresso Jan. 12 at 10:00 PM

$MIRA

0 · Reply

MrWolf19 Jan. 12 at 3:05 PM

$MIRA

0 · Reply

KPW963 Jan. 12 at 1:40 PM

$MIRA

0 · Reply

Jaespresso Jan. 9 at 2:49 PM

$MIRA

0 · Reply

MREricPirate Jan. 9 at 8:48 AM

$MIRA waiting on the MAD results after that they should be starting phase 2 on Ketamir-2

0 · Reply

_Jean123 Jan. 8 at 12:57 AM

0 · Reply

_Jean123 Jan. 8 at 12:02 AM

🚀 $MIRA - FDA DE-RISKED! PHASE 1 SAD SUCCESS IS HERE! 🧪💎 $MIRA JUST PROVED THE SCIENCE! 🛡️ The Phase 1 SAD results are SUCCESSFUL—Ketamir-2 is safe, well-tolerated, and ready for the next level. This isn't just a penny stock anymore; it’s a clinical-stage winner! 🧪 Why this is HUGE: 🚨 SAFETY VALIDATED: Zero serious adverse effects. The system works! FAST TRACK INBOUND: This success opens the door for FDA Fast Track designation THIS quarter. 🚂🔥 MARKET GAP: We are looking at a revolutionary oral Ketamine for depression with a micro-cap valuation. The upside is MASSIVE. 📉 THE CHART: Support at $1.45 is a wall of steel. The "Smart Money" is loading the SAD success while the "Retail" is still sleeping. 😴💤 🎯 TARGET 1: $2.95 (Short term gap fill) 🎯 TARGET 2: $6.00+ (Post-FDA Fast Track news) LOAD THE DIP. TRUST THE SCIENCE. JOIN THE RUN! 🚀🚀🚀 #MIRA #FDA #Biotech #Success #Ketamine #Moonshot #ClinicalTrial #SADSuccess

2 · Reply

dover20 Jan. 7 at 11:39 PM

$MIRA

0 · Reply

Jaespresso Jan. 7 at 7:39 PM

$MIRA bring on the news 🆙🔜

0 · Reply

_Jean123 Jan. 7 at 6:29 PM

$MIRA - The Next $AZI Runner? 🏃‍♂️💨 Did you miss the $AZI 70% move? Don't make the same mistake with $MIRA. While $DVLT is flushing, smart money is rotating here. 🔄💰 WHY? ✅ Micro-Cap Engine: Similar structure to the big runners. ✅ FDA Fast Track: Potential catalyst that makes $AZI look small. ✅ Sector Play: Following the $CYBN and $ATAI lead but with 10x more leverage. The volume is still low (46k), but the chart is a coiled spring. 📈 This is where you buy BEFORE the crowd arrives. Targets: $2.95 🎯 | $6.00 🌕 #PennyStocks #StockMarket #Trading #MIRA #AZI #DVLT #Ketamine

1 · Reply